Influvac (Influenza Virus B/Austria/1359417/2021-Like Strain (B/Austria/1359417/2021, Bvr-26), Influenza A/Vic)

The vaccine contains purified viral antigens from selected influenza A and B strains. After intramuscular or subcutaneous injection, these antigens are processed by the immune system, prompting B‑cell and T‑cell activation. This leads to the production of strain‑specific antibodies that provide protective immunity if the person is later exposed to the matching influenza viruses.

The dosage of Influvac is determined by a qualified healthcare professional based on age, health status, and local immunization guidelines. Typically, a single dose is administered to each eligible individual, with repeat dosing recommended annually according to public‑health recommendations.

Influvac may be administered during pregnancy when the potential benefits outweigh any theoretical risks, but the decision should be made by a healthcare provider. Limited data are available for breastfeeding mothers; however, inactivated influenza vaccines are generally considered compatible with lactation.

To order Influvac, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets. After receiving the request, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including cold‑chain logistics where applicable) and any necessary import documentation.

Influvac contains specific strains (influenza B/Austria/1359417/2021‑like and influenza A/Vic) selected for the current season, similar to other quadrivalent or trivalent formulations. Its safety profile and immunogenicity are comparable to other licensed influenza vaccines, but the exact strain composition may differ, influencing regional effectiveness based on circulating viruses.

Influvac must be stored at 2‑8 °C (refrigerated). Keep the vials in the original packaging, protect them from light, and avoid freezing or shaking. Temperature excursions should be documented, and any product that has been exposed to temperatures outside the recommended range should be discarded.

Influvac is administered by a qualified healthcare professional via intramuscular or subcutaneous injection, typically into the deltoid muscle of the upper arm. The injection site should be cleaned with an appropriate antiseptic before administration, and the patient should be observed for a short period after vaccination for any immediate reactions.

Serious adverse events, although rare, include anaphylaxis, severe allergic reactions, Guillain‑Barré syndrome, high fever, seizures, and acute respiratory distress. Prompt medical attention is required if any of these symptoms develop after vaccination.

Individuals with a known severe allergy to any component of Influvac or to previous influenza vaccines should not receive it. Persons who have experienced a severe reaction to a prior dose of this vaccine should also avoid further administration. Consultation with a healthcare provider is essential for anyone with underlying immunological concerns.